摘要
〔目的）观察去甲长春碱联合化疗对晚期非小细胞肺癌的疗效和耐受住。〔方法〕从1995年10月至1997年10月，36例晚期非小细胞肺癌患者接受以去甲长春减为主的联合化疗，化疗方案为NP、NEP和MNP方案。（结果）总有效率为472％，其中CR3例，PR14例。女性、PSI级、初治者、腺癌、Ⅲ期、MNP方案和NVB剂量40mg／次有效率较高，其中Ⅲ期患者疗效高于Ⅳ期，有显著性差异（P＜0．05），其余无统计学差异（P＞0．05）。中位缓解或6．3个月，中位生存期9个月。主要毒性为白细胞减少，Ⅲ～Ⅳ度减少占33．3％（病例数）和19．1％（周期效）。血红蛋白减少发生率为38．9／（病例数）和23.6％（周期数），血小板减少为22．2％（病例数）和14．5％（周期数）。恶心、呕吐发生率为55．5％，脱发38，9％，静腺炎25．0％，便秘16．7％。〔结论）去甲长春碱联合化方治疗非小细胞肺癌有效，且毒性可耐受。MNP方案值得进一步研究。
(Purposee) To evaluate efficacy and safety prohle of vinorelbine-besed combination chemotherapy in advanced non-small cell lung cancer(NSCLC). (Methods) From October 1995 to October 1997, thirty-six patients received vinorelbine-based combination chrmotherapy with NP, NEP and MNP regimens. [Results] The overall response rate was 47. 2% with three complete responses (CRs) and forteen partial responses(PRs). The median time to progression was 6. 3 months and the median overall survival time was 9months. Grade 3~4 leukopenia was occurred in 33. 3% of patients and 19. 1 % of cycles. Thrombopenia and anemia were uncommon,Other relative frequent side effect were alopecia(38. 9% ), nausea and vomiting (55. 5 % ), phlebitis (25. 0% ), as well as constipation (16. 7%). (Conclusions) This study shows that vinorelbine-based combination chemotherapy is active and tolerable in advanced NSCLC, MNP regimen should be further studied.
